EFG Asset Management North America Corp. Buys 19,363 Shares of Repligen Corporation $RGEN

EFG Asset Management North America Corp. increased its holdings in Repligen Corporation (NASDAQ:RGEN) by 149.8% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 32,286 shares of the biotechnology company’s stock after purchasing an additional 19,363 shares during the period. EFG Asset Management North America Corp. owned approximately 0.06% of Repligen worth $4,015,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Price T Rowe Associates Inc. MD raised its holdings in Repligen by 6.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 7,566,093 shares of the biotechnology company’s stock worth $962,711,000 after purchasing an additional 430,039 shares in the last quarter. Geneva Capital Management LLC raised its holdings in Repligen by 239.6% in the 2nd quarter. Geneva Capital Management LLC now owns 487,534 shares of the biotechnology company’s stock worth $60,639,000 after purchasing an additional 343,991 shares in the last quarter. Nuveen LLC bought a new position in Repligen in the 1st quarter worth $35,536,000. T. Rowe Price Investment Management Inc. raised its holdings in Repligen by 64.0% in the 1st quarter. T. Rowe Price Investment Management Inc. now owns 260,848 shares of the biotechnology company’s stock worth $33,191,000 after purchasing an additional 101,791 shares in the last quarter. Finally, Alyeska Investment Group L.P. raised its holdings in Repligen by 24.0% in the 1st quarter. Alyeska Investment Group L.P. now owns 460,237 shares of the biotechnology company’s stock worth $58,561,000 after purchasing an additional 89,057 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Repligen Stock Down 2.2%

NASDAQ:RGEN opened at $146.93 on Wednesday. The firm has a market cap of $8.27 billion, a P/E ratio of 7,350.18, a P/E/G ratio of 3.32 and a beta of 1.08. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.32 and a current ratio of 8.59. Repligen Corporation has a fifty-two week low of $102.96 and a fifty-two week high of $182.52. The firm has a 50-day simple moving average of $136.52 and a two-hundred day simple moving average of $129.15.

Repligen (NASDAQ:RGEN) last released its quarterly earnings data on Tuesday, October 28th. The biotechnology company reported $0.46 earnings per share for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. The business had revenue of $188.80 million during the quarter, compared to analyst estimates of $181.23 million. Repligen had a net margin of 0.25% and a return on equity of 4.70%. Repligen’s revenue was up 21.9% compared to the same quarter last year. During the same period last year, the business earned $0.43 EPS. Repligen has set its FY 2025 guidance at 1.650-1.680 EPS. Analysts predict that Repligen Corporation will post 1.72 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have commented on RGEN shares. Stephens upgraded shares of Repligen to an “overweight” rating and set a $160.00 price objective for the company in a report on Tuesday, July 22nd. Wells Fargo & Company decreased their price objective on shares of Repligen from $180.00 to $175.00 and set an “overweight” rating for the company in a report on Wednesday, July 30th. Jefferies Financial Group set a $160.00 price target on shares of Repligen and gave the stock a “hold” rating in a research note on Tuesday, October 28th. Weiss Ratings reiterated a “sell (d)” rating on shares of Repligen in a research note on Wednesday, October 8th. Finally, Barclays increased their price target on shares of Repligen from $160.00 to $175.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 29th. One investment analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $173.85.

Insiders Place Their Bets

In other news, Director Martin D. Madaus acquired 1,800 shares of Repligen stock in a transaction on Friday, August 8th. The stock was acquired at an average cost of $112.13 per share, for a total transaction of $201,834.00. Following the purchase, the director owned 1,800 shares in the company, valued at $201,834. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 1.20% of the company’s stock.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.